US Bancorp DE Raises Stock Position in Biohaven Ltd. (NYSE:BHVN)

US Bancorp DE boosted its position in shares of Biohaven Ltd. (NYSE:BHVN) by 36.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,971 shares of the company’s stock after purchasing an additional 798 shares during the period. US Bancorp DE’s holdings in Biohaven were worth $111,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Amalgamated Bank raised its stake in Biohaven by 21.9% during the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company’s stock worth $109,000 after purchasing an additional 527 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Biohaven by 9.1% in the 4th quarter. Bank of New York Mellon Corp now owns 295,078 shares of the company’s stock valued at $11,021,000 after acquiring an additional 24,703 shares during the period. Handelsbanken Fonder AB raised its stake in shares of Biohaven by 20.8% in the 4th quarter. Handelsbanken Fonder AB now owns 25,000 shares of the company’s stock valued at $934,000 after acquiring an additional 4,300 shares during the period. Peregrine Capital Management LLC purchased a new stake in shares of Biohaven in the 4th quarter valued at approximately $5,561,000. Finally, Principal Financial Group Inc. raised its stake in shares of Biohaven by 4.4% in the 4th quarter. Principal Financial Group Inc. now owns 77,387 shares of the company’s stock valued at $2,890,000 after acquiring an additional 3,281 shares during the period. 88.78% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director John W. Childs bought 32,700 shares of the stock in a transaction dated Tuesday, March 4th. The stock was acquired at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the acquisition, the director now owns 2,320,571 shares in the company, valued at approximately $70,707,798.37. This represents a 1.43 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 16.00% of the stock is currently owned by company insiders.

Biohaven Stock Up 3.6 %

NYSE BHVN opened at $29.24 on Monday. Biohaven Ltd. has a 52 week low of $26.80 and a 52 week high of $60.46. The stock has a market capitalization of $2.98 billion, a PE ratio of -3.13 and a beta of 1.27. The firm has a 50 day moving average of $36.87 and a two-hundred day moving average of $42.01.

Biohaven (NYSE:BHVN) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.29). On average, equities research analysts expect that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BHVN has been the topic of a number of research analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 price target on shares of Biohaven in a research note on Tuesday, March 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research note on Tuesday, December 17th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Biohaven in a research note on Tuesday, February 11th. They issued a “buy” rating and a $65.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $54.00 target price on shares of Biohaven in a research note on Tuesday, March 4th. Finally, Morgan Stanley cut their target price on shares of Biohaven from $69.00 to $63.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th. Fourteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $63.15.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.